Experimental immune cell therapy targets Hard-to-Treat cancers

NCT ID NCT05430360

Terminated Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or returned. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are collected from a tumor, multiplied in a lab, and then infused back after a short course of chemotherapy. The study aimed to check safety and whether the treatment could shrink tumors, but it was stopped early after enrolling only 2 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT201 (autologous tumor-infiltrating lymphocyte injection)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have come back or spread.
What could go wrong: This is a very early, small trial (only 2 participants enrolled) that was terminated, so results are limited. The therapy involves strong chemotherapy and may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

The First Hospital of Zhejiang University

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.